Announcing Exceptional Interim Results for 2025

👏 👏 We are excited to announce our interim results for the first half of 2025, showcasing a period of exceptional performance and strategic advancement. These results further solidify our role as a cornerstone of global antibody drug development. Here are the key financial highlights: ✅ Strong Revenue Growth: Reported total revenue of US$101.3 million, representing a 3.27x year-over-year increase. ✅ Sustained Profitability: Achieved a net profit of US$73.0 million, a 51x year-over-year growth. This result marks a major milestone: 2.5 consecutive years of profitability. ✅ Solid Financial Foundation: Maintained a strong cash position with US$320 million in cash and cash equivalents, providing a robust platform for future innovation. Looking ahead, our solid financial foundation enables us to continue accelerating our growth trajectory, pushing the boundaries of innovation, and expanding our global impact. We will: 🌟 Advance our next-generation therapeutics pipeline, 🌟 Enhance our industry-leading technology platforms, 🌟 And drive breakthroughs that shape the future of healthcare. A heartfelt thank you to our dedicated team, visionary partners, and steadfast investors for your incredible support on this journey. Learn more in our full announcement: https://lnkd.in/gpGA892x #FinancialResults #Innovation #Growth #Investors